Hisato Takagi1, Tomo Ando2, Takuya Umemoto3. 1. Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan. Electronic address: kfgth973@ybb.ne.jp. 2. Department of Cardiology, Detroit Medical Center, Detroit, MI, United States. 3. Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan.
Abstract
OBJECTIVES: We summarized comparative studies of MitraClip versus surgical repair for mitral regurgitation (MR) with a systematic literature search and meta-analytic estimates. METHODS: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched through June 2016. Eligible studies were randomized controlled or observational comparative studies of MitraClip versus surgical repair enrolling patients with MR and reporting early (30-day or in-hospital) or late (≥6-month including early) all-cause mortality. For each study, data regarding all-cause mortality and incidence of recurrent >2+ MR in both groups were used to generate odds ratios (ORs). Alternatively, ORs or hazard ratios (HRs) for mortality and recurrent MR themselves were directly abstracted from each study. RESULTS: Eight reports of 7 studies comparing MitraClip with surgical repair enrolling a total of 1015 patients with MR were identified and included. Pooled analyses demonstrated significantly higher age and logistic European System of Cardiac Operative Risk Evaluation and significantly lower ejection fraction in the MitraClip than surgical repair group, no significant difference in rate of women and patients with New York Heart Association functional class of >II, no statistically significant difference in early- (OR, 0.54; p=0.08) and late-mortality (HR/OR, 1.17; p=0.46), and significantly higher incidence of recurrent MR in the MitraClip than surgical repair group (HR/OR, 4.80; p<0.00001). CONCLUSIONS: In patients with MR, the MitraClip procedure achieves similar survival to surgical MV repair despite higher risk profiles. Recurrent MR, however, occurs more frequently (4.8-fold) after the MitraClip than surgical repair.
OBJECTIVES: We summarized comparative studies of MitraClip versus surgical repair for mitral regurgitation (MR) with a systematic literature search and meta-analytic estimates. METHODS: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched through June 2016. Eligible studies were randomized controlled or observational comparative studies of MitraClip versus surgical repair enrolling patients with MR and reporting early (30-day or in-hospital) or late (≥6-month including early) all-cause mortality. For each study, data regarding all-cause mortality and incidence of recurrent >2+ MR in both groups were used to generate odds ratios (ORs). Alternatively, ORs or hazard ratios (HRs) for mortality and recurrent MR themselves were directly abstracted from each study. RESULTS: Eight reports of 7 studies comparing MitraClip with surgical repair enrolling a total of 1015 patients with MR were identified and included. Pooled analyses demonstrated significantly higher age and logistic European System of Cardiac Operative Risk Evaluation and significantly lower ejection fraction in the MitraClip than surgical repair group, no significant difference in rate of women and patients with New York Heart Association functional class of >II, no statistically significant difference in early- (OR, 0.54; p=0.08) and late-mortality (HR/OR, 1.17; p=0.46), and significantly higher incidence of recurrent MR in the MitraClip than surgical repair group (HR/OR, 4.80; p<0.00001). CONCLUSIONS: In patients with MR, the MitraClip procedure achieves similar survival to surgical MV repair despite higher risk profiles. Recurrent MR, however, occurs more frequently (4.8-fold) after the MitraClip than surgical repair.
Authors: Matthias Koschutnik; Varius Dannenberg; Carolina Donà; Christian Nitsche; Andreas A Kammerlander; Sophia Koschatko; Daniel Zimpfer; Martin Hülsmann; Stefan Aschauer; Matthias Schneider; Philipp E Bartko; Georg Goliasch; Christian Hengstenberg; Julia Mascherbauer Journal: J Pers Med Date: 2022-01-11